You are here: Industry Insights > Market News > M&As this week: Eurofins Scientific, Baxter International

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:70500-72-0

Brexpiprazole CAS:913611-97-9

3-BROMOPHENANTHRENE

2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE

3-BROMO-4-FLUOROBIPHENYL

9-TRIFLUOROACETYLANTHRACENE

M&As this week: Eurofins Scientific, Baxter International

pharmaceutical-technologyAugust 07, 2017

Tag: M&As , Eurofins Scientific , Baxter International

Favorites

Luxembourg-based life sciences company Eurofins Scientific plans to acquire DiscoverX, a reagents provider based in the US.

The acquisition will strengthen Eurofins Scientific’s drug discovery services.

"Baxter International has announced the acquisition of Claris Injectables for approximately $625m."

Baxter International has announced the acquisition of Claris Injectables for approximately $625m.

Baxter is a medical products company based in the US, while Claris is an injectables pharmaceutical company based in India.

The acquisition will provide Baxter with access to Claris’ product portfolio and pipeline and strengthen its position in the generic injectable medicines market.

Previous:Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Next:Biopharma stages a strong recovery over the first half even as M&A deals disappoint

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

M&As this week: Eurofins Scientific, Baxter International | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

M&As this week: Eurofins Scientific, Baxter International

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

M&As this week: Eurofins Scientific, Baxter International

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>